👍-To The Moon - Tiger Brokers Online Investing Community - To The Moon

Like
Comment
Favorite

虎头虎脑之鹰击长空
2023-01-16

👍

港股异动 | 科济药业-B(02171)午前涨超12% 核心管线产品CT053在今年有望商业化

智通财经APP获悉，科济药业-B午前涨超12%，截至发稿，涨12.29%，报19.74港元，成交额8656.07万港元。据悉，科济药业核心管线产品为CT053，被开发用于治疗失败的复发或难治性多发性骨髓瘤成年患者，可特异性识别BCMA，令CAR-T细胞能够有效靶向及去除在细胞表面携带BCMA的多发性骨髓瘤细胞。2022年10月18日，CT053新药上市申请获国家药监局受理；此外，CT053在北美正开展Ib/II期临床试验，预计2023年递交BLA。分析表示，CT053在今年有望商业化。

港股异动 | 科济药业-B(02171)午前涨超12% 核心管线产品CT053在今年有望商业化

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Like

Report

Comment

Top
Latest

empty

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":626323471,"tweetId":"626323471","gmtCreate":1673850816795,"gmtModify":1676538894463,"author":{"id":4098320575389210,"idStr":"4098320575389210","authorId":4098320575389210,"authorIdStr":"4098320575389210","name":"虎头虎脑之鹰击长空","avatar":"https://static.tigerbbs.com/0cc990f6c7bc363a015b013ff9572be1","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>👍</p></body></html>","htmlText":"<html><head></head><body><p>👍</p></body></html>","text":"👍","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/626323471","repostId":2303826099,"repostType":2,"repost":{"id":"2303826099","kind":"news","pubTimestamp":1673581680,"share":"https://www.laohu8.com/m/news/2303826099?lang=&edition=full","pubTime":"2023-01-13 11:48","market":"us","language":"zh","title":"港股异动 | 科济药业-B(02171)午前涨超12% 核心管线产品CT053在今年有望商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=2303826099","media":"智通财经","summary":"智通财经APP获悉，科济药业-B午前涨超12%，截至发稿，涨12.29%，报19.74港元，成交额8656.07万港元。据悉，科济药业核心管线产品为CT053，被开发用于治疗失败的复发或难治性多发性骨髓瘤成年患者，可特异性识别BCMA，令CAR-T细胞能够有效靶向及去除在细胞表面携带BCMA的多发性骨髓瘤细胞。2022年10月18日，CT053新药上市申请获国家药监局受理；此外，CT053在北美正开展Ib/II期临床试验，预计2023年递交BLA。分析表示，CT053在今年有望商业化。","content":"<html><body><p>智通财经APP获悉，<a href=\"https://laohu8.com/S/02171\">科济药业-B</a>(02171)午前涨超12%，截至发稿，涨12.29%，报19.74港元，成交额8656.07万港元。</p><p>智通财经APP在《两款CAR-T领跑国内同行，估值仍处于底部的科济药业-B（02171）现补涨行情？》中指出，根据Frost&amp;Sullivan预测，2021年国内CAR-T疗法的市场规模约为人民币2亿元，未来在癌症患者增加、政策优惠、患者负担能力提高的推动下，2030年将增至289亿元，2022年至2030年的复合年增长率高达45.0%。</p><p>据悉，科济药业核心管线产品为CT053，被开发用于治疗失败的复发或难治性多发性骨髓瘤（R/RMM）成年患者，可特异性识别BCMA，令CAR-T细胞能够有效靶向及去除在细胞表面携带BCMA的多发性骨髓瘤细胞。2022年10月18日，CT053新药上市申请获国家药监局受理；此外，CT053在北美正开展Ib/II期临床试验，预计2023年递交BLA。分析表示，CT053在今年有望商业化。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 科济药业-B(02171)午前涨超12% 核心管线产品CT053在今年有望商业化</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 科济药业-B(02171)午前涨超12% 核心管线产品CT053在今年有望商业化\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-01-13 11:48 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/861494.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，科济药业-B(02171)午前涨超12%，截至发稿，涨12.29%，报19.74港元，成交额8656.07万港元。智通财经APP在《两款CAR-T领跑国内同行，估值仍处于底部的科济药业-B（02171）现补涨行情？》中指出，根据Frost&Sullivan预测，2021年国内CAR-T疗法的市场规模约为人民币2亿元，未来在癌症患者增加、政策优惠、患者负担能力提高的推动下，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/861494.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK1585":"昨日强势股","BK1574":"生物医药B类股","BK1161":"生物科技","02171":"科济药业-B","BK1587":"次新股"},"source_url":"http://www.zhitongcaijing.com/content/detail/861494.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2303826099","content_text":"智通财经APP获悉，科济药业-B(02171)午前涨超12%，截至发稿，涨12.29%，报19.74港元，成交额8656.07万港元。智通财经APP在《两款CAR-T领跑国内同行，估值仍处于底部的科济药业-B（02171）现补涨行情？》中指出，根据Frost&Sullivan预测，2021年国内CAR-T疗法的市场规模约为人民币2亿元，未来在癌症患者增加、政策优惠、患者负担能力提高的推动下，2030年将增至289亿元，2022年至2030年的复合年增长率高达45.0%。据悉，科济药业核心管线产品为CT053，被开发用于治疗失败的复发或难治性多发性骨髓瘤（R/RMM）成年患者，可特异性识别BCMA，令CAR-T细胞能够有效靶向及去除在细胞表面携带BCMA的多发性骨髓瘤细胞。2022年10月18日，CT053新药上市申请获国家药监局受理；此外，CT053在北美正开展Ib/II期临床试验，预计2023年递交BLA。分析表示，CT053在今年有望商业化。","news_type":1},"isVote":1,"tweetType":1,"viewCount":163,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}